The use of mycophenolate mofetil (MMF) for prophylaxis of aGVHD and/or for treatment of acute or chronic GVHD is increasing. However, the benefit of MMF as an alternative to commonly used ...

Mycophenolate mofetil is a disease-modifying anti-rheumatic drug (DMARD) used to treat rheumatic diseases such as systemic lupus erythematosus (SLE, lupus), myositis and vasculitis.

Mycophenolate is, however, more expensive than azathioprine. Objective: To compare long-term outcomes with azathioprine and mycophenolate in renal transplant recipients receiving ciclosporin ...

A retrospective review shows that dermatologic patients treated with mycophenolate mofetil face a significantly lower incidence of malignancy than transplant recipients.

Mycophenolate mofetil was administered at a dose of 10 to 15 mg/kg twice daily with a target for mycophenolic acid area under the curve of 30 to 50 μg·h/mL for 6 months, and subsequently ...

Early treatment with mycophenolate mofetil can reduce subsequent risks for severe flares and lupus nephritis in newly diagnosed systemic lupus erythematosus, according to data published in JAMA ...

First, mycophenolate mofetil was compared with oral rather than pulsed intravenous cyclophosphamide, which has become the standard of treatment for patients with diffuse proliferative lupus ...

“Mycophenolate can also be considered as a first-line treatment in combination with systemic corticosteroids in severe morphea.” – by Rob Volansky Disclosures: Arthur and Cruz-Diaz report no ...

The Food and Drug Administration (FDA) has approved Myhibbin ™, a ready-to-use, oral suspension formulation of mycophenolate mofetil. Myhibbin is an antimetabolite immunosuppressant indicated ...

Six disease flares occurred in the rituximab group compared with 44 in the mycophenolate mofetil group (adjusted rate ratio, 0.12). The mean change in the Dermatology Life Quality Index score was ...

Quick Take Rituximab versus Mycophenolate Mofetil in Patients with Pemphigus Vulgaris DOI: 10.1056/NEJMdo006053 Save ...